Inventor
KORBER BETTE T
US31 patents
⚠️ This page may combine multiple inventors who share the name “KORBER BETTE T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV DUKE
14 patentsUS10149902B2Dec 11, 2018
Swarm immunization with envelopes from CH505
UNIV DUKE7 citations83
US10004800B2Jun 26, 2018
Antibody evolution immunogens
UNIV DUKE6 citations82
US10076567B2Sep 18, 2018
MPER-liposome conjugates and uses thereof
UNIV DUKE3 citations72
US9821053B2Nov 21, 2017
Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins
UNIV DUKE2 citations72
US10968255B2Apr 6, 2021
Compositions comprising HIV envelopes to induce CH235 lineage antibodies
UNIV DUKE2 citations71
US11246920B2Feb 15, 2022
Compositions and methods for inducing HIV-1 antibodies
UNIV DUKE2 citations70
US11884704B2Jan 30, 2024
Compositions comprising HIV envelopes to induce CH235 lineage antibodies
UNIV DUKE0 citations60
US9492532B2Nov 15, 2016
Nucleic acids encoding mosaic HIV-1 gag proteins
UNIV DUKE2 citations60
US10946090B2Mar 16, 2021
Consensus/ancestral immunogens
UNIV DUKE0 citations59
US12559527B2Feb 24, 2026
Compositions comprising V2 opt HIV envelopes
UNIV DUKE0 citations57
US10906941B2Feb 2, 2021
Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage
UNIV DUKE0 citations56
US10849970B2Dec 1, 2020
Antibody evolution immunogens
UNIV DUKE0 citations51
US10232034B2Mar 19, 2019
Compositions comprising CH505 envelopes, and trimers
UNIV DUKE0 citations51
US10322141B2Jun 18, 2019
Compositions comprising CH848 envelopes and uses thereof
UNIV DUKE0 citations40
BETH ISRAEL DEACONESS MEDICAL CT INC
5 patentsUS9670253B2Jun 6, 2017
Antiviral vaccines with improved cellular immunogenicity
BETH ISRAEL DEACONESS MEDICAL CT INC4 citations83
US11331386B2May 17, 2022
Antiviral vaccines with improved cellular immunogenicity
BETH ISRAEL DEACONESS MEDICAL CT INC0 citations62
US11230572B2Jan 25, 2022
Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
BETH ISRAEL DEACONESS MEDICAL CT INC1 citations57
US10772952B2Sep 15, 2020
Antiviral vaccines with improved cellular immunogenicity
BETH ISRAEL DEACONESS MEDICAL CT INC0 citations51
US10426831B2Oct 1, 2019
Antiviral vaccines with improved cellular immunogenicity
BETH ISRAEL DEACONESS MEDICAL CT INC0 citations51
KORBER BETTE T
4 patentsUS9044445B2Jun 2, 2015
Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
KORBER BETTE T4 citations82
US9011873B2Apr 21, 2015
Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
KORBER BETTE T4 citations82
US9011875B2Apr 21, 2015
Human immunodeficiency virus type 1 clade M mosaic gag polypeptides
KORBER BETTE T5 citations81
US8119140B2Feb 21, 2012
Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
KORBER BETTE T12 citations81
LOS ALAMOS NAT SECURITY LLC
2 patentsUNIV CALIFORNIA
2 patentsHAYNES BARTON F
2 patentsUS8071107B2Dec 6, 2011
Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
HAYNES BARTON F26 citations89
US9844589B2Dec 19, 2017
Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses
HAYNES BARTON F2 citations70